Role of formyl peptide receptors (FPR) in abnormal inflammation responses involved in neurodegenerative diseases

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2012, Pages 20-36

  Mollica, Adriano ^a   Stefanucci, Azzurra ^b   Costante, Roberto ^a   Pinnen, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ALS; Alzheimer's disease; FPR; Glia; Neurodegenerative diseases; Parkinson's disease; Prion diseases; SAA

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; COMPOUND 2992722; CYTOKINE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR ANTAGONIST; MW01 070C; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATION; MICROGLIA; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 84867516946     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803476246     Document Type: Review

References (96)

1. Liang, T.S.; Wang, J.M.; Murphy, P.M.; Gao, J.L. Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem. and Biophys. Res. Comm., 2000, 270, 331-335.
2. Selvatici, R.; Falzarano, S.; Mollica, A.; Spisani, S. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur. J. Pharmacol., 2006, 534, 1-11.
3. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308, 1314-1318.
4. Wake, H.; Moorhouse, A.J.; Jinno, S.; Kohsaka, S.; Nabekura, J. Resting Microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci., 2009, 29, 3974-3980.
5. Roumier, A.; Bechade, C.; Poncer, J.C.; Smalla, K.H.; Tomasello, E.; Vivier, E.; Gundelfinger, E.D.; Triller, A.; Bessis, A. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J. Neurosci., 2004, 24, 11421-11428.
6. Marin-Teva, J.L.; Dusart, I.; Colin, C.; Gervais, A.; Van, R.N.; Mallat, M. Microglia promote the death of developing Purkinje cells. Neuron, 2004, 41, 535-547.
7. Le, Y.; Baoqun, Li.; Gong, W.; Shen, W.; Hu, J.; Dunlop, N.M.; Oppenheim, J.J.; Wang, J.M. Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol. Rev., 2000, 177, 185-194.
8. Cabral, G.A.; Cabral, F.M. Cannabinoid receptors in microglia of the central nervous system: Immune functional relevance. J. of Leuk. Biol., 2005, 78, 1192-1197.
9. Benito, C.; Nunez, E.; Tolon, R.M.; Carrier, E.J.; Rabano, A.; Hillard, C.J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaqueassociated glia in Alzheimer's disease brains. J. Neurosci., 2003, 23, 11136-11141.
10. Pagani Zecchini, G.; Nalli, M.; Mollica, A.; Lucente, G.; Paglialunga Paradisi, M.; Spisani, S. Isopeptide bonds in chemotactic tripeptides. Synthesis and activity of lysine-containing fMLF analogs. J. Pept. Res., 2002, 59, 283-291.
11. Mollica, A.; Paradisi, Paglialunga, M.; Varani, K.; Spisani S.; Lucente, G. Chemotactic peptides: fMLF-OMe analogues incorporating proline-methionine chimeras as N-terminal residue. Bioorg. Med. Chem., 2006, 14, 2253-2265.
12. Mollica, A.; Paglialunga Paradisi, M.; Torino, D.; Spisani, S.; Lucente, G. Hybrid α/β-peptides: For-Met-Leu-Phe-OMe analogues containing geminally disubstituted β2,2-and β3,3-amino acids at the central position. Amino Acids, 2006, 30, 453-459.
13. Selvatici, R.; Falzarano, S.; Franceschetti, L.; Mollica, A.; Guerrini, R.; Siniscalchi, A.; Spisani, S. Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH. FEBS J., 2008, 275, 449-457.
14. Torino, D.; Mollica, A.; Pinnen, F.; Feliciani, F.; Spisani, S.; Lucente, G. Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on met residue replacement by 4-amino-proline scaffold: Synthesis and bioactivity. Bioorg. Med. Chem., 2009, 1, 251-259.
15. Rogers, J.; Lue, L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int., 2001, 39, 333-340.
16. Le, Y.; Gong, W.; Tiffany, H.L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N.M.; Gao, J.L.; Murphy, P.M.; Oppenheim, J.J.; Wang, J.M. Amyloid β42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci., 2001, 21, RC123.
17. 3-peptides with proteinogenic side chains. Monosubstituted analogues of the chemotactic tripeptide For-Met-Leu-Phe-OMe. J Pept. Sci., 2004, 10, 10-23.
18. Takenouchi, T.; Munekata, E. β-Amyloid peptide, substance P, and SEC receptor ligand activate cytoplasmic Ca2+ in neutrophil-like HL-60 cells: Effect of chemotactic peptide antagonist BocMLF. Peptides, 1995, 16, 1019-1024.
19. Bae, Y.S.; Lee, H.Y.; Jo, E.J.; Kim, J.I.; Kang, H.K.; Ye, R.D.; Kwak, J.Y.; Ryu, S.H. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J. Immunol., 2003, 171, 6807-6813.
20. Tiffany, H.L.; Lavigne, M.C.; Cui, Y.H.; Wang, J.M.; Leto, T.L.; Gao, J.L.; Murphy, P.M. Amyloid-β induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G proteincoupled receptor expressed in phagocytes and brain. J. Biol. Chem., 2001, 276, 23645-23652.
21. Yazawa, H.; Yu, Z.X.; Takeda, K.; Le, Y.; Gong, W.; Ferrans, V.J.; Oppenheim, J.J.; Li, C.C.; Wang, J.M. β Amyloid peptide (Aβ42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J., 2001, 15, 2454-2462.
22. Shin, E.H.; Lee, H.Y.; Kim, S.D.; Jo, S.H.; Kim, M.K.; Park, K.S.; Lee, H.; Bae, Y.S.; Trp-Arg-Trp-Trp-Trp-Trp antagonizes formyl peptide receptor like 2-mediated signaling. Biochem. Biophys. Res. Comm., 2006, 341, 1317-1322.
23. Kang, H.K.; Lee, H.Y.; Kim, M.K.; Park, K.S.; Park, J.M.; Kwak, J.Y.; Bae, Y.S. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met inhibits human monocyte-derived dendritic cell maturation via formyl peptide receptor and formyl peptide receptor-like 2. J. Immunol., 2005, 175, 685-692.
24. Yang, D.; Chen, Q.; Gertz, B.; He, R.; Phulsuksombati, M.; Ye, R.D.; Oppenheim, J.J. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J. Leukoc. Biol., 2002, 72, 598-607.
25. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature, 1998, 392, 245-252.
26. Su, X.; Maguire-Zeiss, K.A.; Giuliano, R.; Prifti, L.; Venkatesh, K.; Federhoff, H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging, 2007, 29, 1690-1701.
27. Prinz, M.; Priller, J. Tickets to the brain: Role of CCR2 and CX(3)CR1in myeloid cell entry in the CNS. J. Neuroimmunol., 2010, 224, 80-84.
28. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLAβDR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38, 1285-1291.
29. Liberatore, G.T.; Jackson-Lewis, V.; Vukosavic, S.; Mandir, A.S.; Vila, M.; McAuliffe, W.G.; Dawson, V.L.; Dawson, T.M.; Przedborski, S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 1999, 5, 1403-1409.
30. Wu, D.C.; Teismann, P.; Tieu, K.; Vila, M.; Jackson-Lewis, V.; Ischiropoulos, H.; Przedborski, S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 6145-6150.
31. Liu, K.; Victora, G.D.; Schwickert, T.A.; Guermonprez, P.; Meredith, M.M.; Yao, K.; Chu, F.F.; Randolph, G.J.; Rudensky, A.Y.; Nussenzweig, M. In vivo analysis of dendritic cell development and homeostasis. Science, 2009, 324, 392-397.
32. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest., 2009, 119, 182-192.
33. McGeer, E.G.; McGeer, P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs, 2007, 21,789-797.
34. Chen, H., Zhang, S.M., Hernán, M.A., Schwarzschild, M.A., Willett, W.C., Colditz, G.A., Speizer, F.E., Ascherio, A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch. Neurol., 2003, 60, 1065-1073.
35. Chen, H.; Jacobs, E.; Schwarzschild, M.A.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol., 2005, 58, 963-967.
36. El Khoury, J.; Toft, M.; Hickman, S.E.; Means, T.K.; Terada, K.; Geula, C.; Luster, A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med., 2007, 13, 432-438.
37. Mildner, A.; Schmidt, H.; Nitsche, M.; Merkler, D.; Hanisch, U.K.; Mack, M.; Heikenwalder, M.; Bruck, W.; Priller, J.; Prinz, M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci., 2007, 10, 1544-1553.
38. Kalkonde, Y.V.; Morgan, W.W.; Sigala, J.; Maffi, S.K.; Condello, C.; Kuziel, W.; Ahuja, S.S.; Ahuja, S.K. Chemokines in the MPTP model of Parkinson's disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res., 2007, 1128, 1-11.
39. Sharp, B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav. Immun., 2006, 20, 9-14.
40. Wang, V.; Chia, L.G.; Ni, D.R.; Cheng, L.J.; Ho, Y.P.; Cheng, F.C.; Hong, J.S. Effects of the combined treatment of naloxone and indomethacin on catecholamines and behavior after intranigral lipopolysaccharide injection. Neurochem. Res., 2004, 29, 341-346.
41. Liu, Y.; Qin, L.; Wilson, B.C.; An, L.; Hong, J.S. Inhibition by naloxone stereoisomers of β-amyloid peptide(1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J. Pharmacol. Exp. Ther., 2002, 302, 1212-1219.
42. Liu, Y.; Qin, L.; Li, G.; Zhang, W.; An, L.; Liu, B.; Hong, J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther., 2003, 305, 212-218.
43. Vaglini, F.; Pardini, C.; Bonuccelli, U.; Maggio, R.; Corsini, G.U. Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice. Brain Res., 2003, 973, 298-302.
44. Beers, D.R.; Henkel, J.S.; Xiao, Q.; Zhao, W.; Wang, J.; Yen, A.A.; Siklos, L.; McKercher, S.R.; Appel, S.H. Wild-type microglia extend survival in PU.1 knockoutmice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2006, 103, 16021-16026.
45. Boillee, S.; Vande, V.C.; Cleveland, D.W. ALS: A disease of motor neurons and their non-neuronal neighbors. Neuron, 2006, 52, 39-59.
46. Xiao, S.; Sato, C.; Kawarai, T.; Goodall, E.F.; Pall, H.S.; Zinman, L.H.; Robertson, J.; Morrison, K.; Rogaeva, E. Genetic studies of GRN and IFT74 in amyotrophic lateral sclerosis. Neurobiol. Aging, 2008, 29, 1279-1282.
47. Gowing, G.; Lalancette-Hebert, M.; Audet, J.N.; Dequen, F.; Julien, J.P. Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase Exp. Neurol., 2009, 220, 267-275.
48. Solomon, J.N.; Lewis, C.A.; Ajami, B.; Corbel, S.Y.; Rossi, F.M.; Krieger, C. Origin and distribution of bone marrow-derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis. Glia, 2006, 53, 744-753.
49. Appel, S.H.; Engelhardt, J.I.; Henkel, J.S.; Siklos, L.; Beers, D.R.; Yen, A.A.; Simpson, E.P.; Luo, Y.; Carrum, G.; Heslop, H.E.; Brenner, M.K.; Popat, U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology, 2008, 71, 1326-1334.
50. Ajami, B.; Bennett, J.L.; Krieger, C.; Tetzlaff, W.; Rossi, F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci., 2007, 10, 1538-1543.
51. Harraz, M.M.; Park, A.; Abbott, D.; Zhou, W.; Zhang, Y.; Engelhardt, J.F. MKK6 phosphorylation regulates production of superoxide by enhancing Rac GTPase activity. Antioxid. Redox Signal., 2007, 9, 1803-1813.
52. Harraz, M.M.; Marden, J.J.; Zhou, W.; Zhang, Y.; Williams, A.; Sharov, V.S.; Nelson, K.; Luo, M.; Paulson, H.; Schöneich, C.; Engelhardt, J.F. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest., 2008, 118, 659-670.
53. Tremblay, M.E.; Stevens, B.; Sierra, A.; Wake, H.; Bessis, A.; Nimmerjahn, A. Mini-symposium: The role of microglia in the healthy brain. J. Neurosci., 2011, 31, 16064-16069.
54. D'Ambrosi, N.; Finocchi, P.; Apolloni, S.; Cozzolino, M.; Ferri, A.; Padovano, V.; Pietrini, G.; Carrì, M.T.; Volonté, C. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol., 2009, 183, 4648-4656.
55. Giese, A.; Groschoup, M.H.; Hess, B.; Kretzschmar, H.A. Neuronal cell death in scrapie-infected mice is due to apoptosis. Brain Pathol., 1995, 5, 213-221.
56. Brown, D.R.; Goller, N.L.; Rudelli, R.D.; Merz, G.S.; Wolfe, G.C.; Wisniewski, H.M.; Robakis, N.K. The mRNA encoding the scrapie agent protein is present in a variety of non-neuronal cells. Acta Neuropathol., 1990, 80, 1-6.
57. Jackson, G.S.; Clarke, A.R. Mammalian prion proteins. Curr. Opin. Struct. Biol., 2000, 10, 69-74.
58. Prusiner, S.B. The priori diseases. Brain Pathol., 1998, 8, 499-513.
59. Brown, D.R.; Kretzschmar, H.A. Microglia and prion disease: a review. Histol. Histopathol., 1997, 12, 883-892.
60. Le, Y.; Yazawa, H.; Gong, W.; Yu, Z.; Ferrans, V.J.; Murphy, P.M.; Wang, J.M. The neurotoxic prion peptide fragment PrP (106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J. Immunol., 2001, 166, 1448-1451.
61. Kaneko, Y.; Kitamoto, T.; Tateishi, J.; Yamaguchi, K. Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathol., 1989, 79, 129-136.
62. Guiroy, D.C.; Wakayama, I.; Liberski, P.P.; Gaydusek, D.C. Relationship of microglia and scrapie amyloid-immunoreactive plaques in kuru, Creutzfeldt-Jakob disease and Gerstmann-Sträußler syndrome. Acta Neuropathol., 1994, 87, 526-530.
63. Fraser, H.; Dickinson, A.G. Studies of the lymphoreticular system in the pathogenesis of scrapie: The role of spleen and thymus. J. Comp. Pathol., 1978, 88, 563-573.
64. Masters, C.L.; Richardson, E.P. Jr. Subacute spongiform encephalopathy (Creutzfeldt-Jakob disease). The nature and progression of spongiform change. Brain, 1978, 101, 333-344.
65. Brown, D.R.; Besinger, A.; Herms, J.W.; Kretzschmar, H.A. Microglial expression of the prion protein. Neuroreport, 1998, 9, 1425-1429.
66. Brown, D.R.; Mohn, C.M. Astrocytic glutamate uptake and prion protein expression. Glia, 1999, 25, 282-292.
67. Barcikowska, M.; Liberski, P.P.; Boellaard, J.W.; Brown, P.; Gaydusek, D.C.; Budka, H. Microglia is a component of the prion protein amyloid plaque in the Gerstmann-Sträussler-Scheinker syndrome. Acta Neuropathol., 1993, 85, 623-627.
68. Eitzen, U.; Egensperger, R.; Kösel, S.; Grasbon-Frodl, E.M.; Imai, Y.; Bise, K.; Kohsaka, S.; Mehraein, P.; Graeber, M.B. Microglia and the development of spongiform change in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol., 1998, 57, 246-256.
69. Aldskogius, H.; Kozlova, E.N. Central neuron-glial and glialglial interactions following axon injury. Prog. Neurobiol., 1998, 55, 1-26.
70. Avellino, A.M.; Hart, D.; Dailey, A.T.; MacKinnon, M.; Ellegala, D.; Kliot, M. Differential macrophage responses in the peripheral and central nervous system during Wallerian degeneration of axons. Exp. Neurol., 1995, 136, 183-198.
71. Bacon, K.B.; Harrison, J.K. Chemokines and their receptors in neurobiology: Perspectives in physiology and homeostasis. J. Neuroimmunol., 2000, 104, 92-97.
72. Richardson, P.M.; Lu, X. Inflammation and axonal regeneration. J. Neurol., 1994, 242, S57-S60.
73. Lazarov-Spiegler, O.; Solomon, A.S.; Schwartz, M. Peripheral nerve-stimulated macrophages simulate a peripheral nerve-like regenerative response in rat transected optic nerve. Glia, 1998, 24, 329-337.
74. Lazarov-Spiegler, O.; Soloman, A.S.; Zeev-Brann, A.B.; Hirschberg, D.L.; Lavie, V.; Schwartz, M. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB J., 1996, 10, 1296-1302.
75. Nona, S.N.; Thomlinson, A.M.; Stafford, C.A. Temporary colonization of the site of lesion by macrophages is a prelude to the arrival of regenerated axons in injured goldfish optic nerve. J. Neurocytol., 1998, 27, 791-803.
76. Rogers, J.; Mastroeni, D.; Leonard, B.; Joyce, J.; Grover, A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: Are microglia pathogenic in either disorder? Int. Rev. Neurobiol., 2007, 82, 235-246.
77. Lai, A.Y.; McLaurin, J. Clearance of amyloid-β peptides by microglia and macrophages: The issue of what, when and where. Future Neurol., 2012, 7, 165-176.
78. Streit, W.J.; Braak, H.; Xue, Q.S.; Bechmann, I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol., 2009, 118, 475-485.
79. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
80. Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature, 2002, 415, 462.
81. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Aβ42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet, 2008, 372, 216-223.
82. Boissonneault, V.; Filali, M.; Lessard, M.; Relton, J.; Wong, G.; Rivest, S. Powerful beneficial effects of macrophage colonystimulating factor on β-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain, 2009, 132, 1078-1092.
83. Sanchez-Ramos, J.; Song, S.; Sava, V.; Catlow, B.; Lin, X.; Mori, T.; Cao, C.; Arendash, G.W. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neurosci., 2009, 163, 55-72.
84. Grathwohl, S.A.; Kalin, R.E.; Bolmont, T.; Prokop, S.; Winkelmann, G.; Kaeser, S.A.: Odenthal, J.; Radde, R.; Eldh, T.; Gandy, S.; Aguzzi, A.; Staufenbiel, M.; Mathews, P.M.; Wolburg, H.; Heppner, F.L.; Jucker, M. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nat. Neurosci., 2009, 12, 1361-1363.
85. Lim, G.P.; Yang, F.; Chu, T.; Gahtan, E.; Ubeda, O.; Beech, W.; Overmier, J.B.; Hsiao-Ashec, K.; Frautschy, S.A.; Cole, G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging, 2001, 22, 983-991.
86. Watterson, D.M.; Mirzoeva, S.; Guo, L.; Whyte, A.; Bourguignon, J.J.; Hibert, M.; Haiech, J.; Van Eldik, L.J. Ligand modulation of glial activation: Cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin 1β and nitric oxide synthase II. Neurochem. Int., 2001, 39, 459-468.
87. Craft, J.M.; Watterson, D.M.; Frautschy, S.A.; Van Eldik, L. Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo. J. Neurobiol. Aging, 2004, 25, 1283-1292.
88. Frautschy, S.A.; Hu, W.; Kim, P.; Miller, S.A.; Chu, T.; Harris-White, M.E.; Cole, G.M. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. J. Neurobiol. Aging, 2001, 22, 993-1005.
89. Young, S.M.; Bologa, C.M.; Fara, D.; Bryant, B.K.; Strouse, J.J.; Arterburn, J.B.; Ye, R.D.; Oprea, T.I.; Prossnitz, E.R.; Sklar, L.A.; Edwards, B.S. Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. Cytometry A., 2009, 75, 253-263.
90. Cilibrizzi, A.; Quinn, M.T.; Kirpotina, L.N.; Schepetkin, I.A.; Holderness, J.; Ye, R.D.; Rabiet, M.J.; Biancalani, C.; Cesari, N.; Graziano, A.; Vergelli, C.; Pieretti, S.; Dal Piaz, V.; Giovannoni, M.P. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: A novel class of small-molecule agonists for formyl peptide receptors. J. Med. Chem., 2009, 52, 5044-5057.
91. Traynor, B.J.; Bruijn, L.;. Conwit, R.; Beal, F.; O'Neill, G., Fagan, C., Cudkowicz, M.E. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology, 2006, 67, 20-27.
92. Gordon, P.H.; Cheung, Y.K.; Levin, B.; Andrews, H.; Doorish, C.; Macarthur, R.B.; Montes, J.; Bednarz, K.; Florence, J.; Rowin, J.; Boylan, K.; Mozaffar, T.; Tandan, R.; Mitsumoto, H.; Kelvin, E.A.; Chapin, J.; Bedlack, R.; Rivner, M.; McCluskey, L.F.; Pestronk, A.; Graves, M.; Sorenson, E.J.; Barohn, R.J.; Belsh, J.M.; Lou, J.S.; Levine, T.; Saperstein, D.; Miller, R.G.; Scelsa, S.N. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral Scler., 2008, 9, 212-222.
93. Kim, J-M.; Chang, H.J.; Kim, W-K.; Chang, N.; Chin, H.S. Structure-activity relationshio of neuroprotective and reactive oxygen species scavenging activities for allium organosulfur compounds. J. Agric. Food. Chem. 2006, 54, 6547-6553.
94. Morera, E.; Nalli, M.; Mollica, A.; Paglialunga Paradisi, M.; Aschi, M.; Gavuzzo, E.; Mazza, F.; Lucente, G. Peptides containing 4-amino-1,2-dithiolane-4-carboxylic acid (Adt): conformation of Boc-Adt-Adt-NHMe and NH···S interactions. J. Pept. Sci. 2005, 11, 104-112.
95. Torino, D.; Mollica, A.; Pinnen, F.; Lucente, G.; Feliciani, F.; Davis, P.; Lai, J.; Ma, S.-W., Porreca, F.; Hruby, V. J. Synthesis and evaluation of new endomorphin analogues modifies at the Pro2 residue. Bioorg. Med. Chem. Lett. 2009, 19, 4115-4118.
96. Szegedi, V.; Juhàsz, G.; Ròzsa, E.; Gabriella, J.V.; Datki, Z.; Fulop, L.; Bozsò, Z.; Lakatos, A.; Laczkò, I.; Farkas, T.; Kis, Z.; Tòth, G.; Soòs, K.; Zaràndi, M.; Budai, D.; Toldi, J.; Penke, B. Endomorphin-2, an endogenous tetrapeptide, protects against Ab1-42 in vitro and in vivo. FASEB J. 2006, 20, 1191-1193.